In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Shionogi & Co. Ltd.

http://www.shionogi.co.jp/index.html

Latest From Shionogi & Co. Ltd.

The Serious Business Of Digital Medical Games

Bookmark
  • Analysis
By David Wild

There are fewer than a handful of approved prescription video game digital therapeutics, but gamification in patient care is proving its worth as a novel way of treating a range of conditions, from vision loss to dyslexia and ADHD. Now, the onus is on lawmakers and insurers to create a clear path towards reimbursement.

Behavioral Health Digital Health

New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

Bookmark
  • Analysis
By Ian Haydock

After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.

Japan Business Strategies

Japan Co-Logistics Project Aims For Efficiency, Compliance

Bookmark
  • Analysis
By Lisa Takagi

Three Japanese pharma firms say their new joint logistics project will help more efficient distribution to wholesalers, optimize delivery labor in an ageing society and comply with tightening regulations.

Japan Strategy

New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

Bookmark
  • Analysis
By Ian Haydock

After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures. 

Japan Scrip Perspectives
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Shionogi Healthcare Co., Ltd
    • Shionogi Pharma Co., Ltd
    • Shionogi Techno Advance Research Co., Ltd.
    • Shionogi Administration Service Co., Ltd.
    • Shionogi Business Partner Co., Ltd
    • Shionogi Marketing Solutions Co., Ltd
    • Shionogi Career Development Center Co., Ltd.
    • Shionogi Digital Science Co., Ltd.
    • Shionogi Pharmacovigilance Center Co., Ltd.
    • Aburahi AgroResearch Co., Ltd.
    • Shionogi Smile Heart Co., Ltd
    • UMN Pharma Inc.
    • Shionogi B.V.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By